BR112022004465A2 - Método para a prevenção, retardo de progressão ou tratamento de câncer em um sujeito e combinação farmacêutica - Google Patents

Método para a prevenção, retardo de progressão ou tratamento de câncer em um sujeito e combinação farmacêutica

Info

Publication number
BR112022004465A2
BR112022004465A2 BR112022004465A BR112022004465A BR112022004465A2 BR 112022004465 A2 BR112022004465 A2 BR 112022004465A2 BR 112022004465 A BR112022004465 A BR 112022004465A BR 112022004465 A BR112022004465 A BR 112022004465A BR 112022004465 A2 BR112022004465 A2 BR 112022004465A2
Authority
BR
Brazil
Prior art keywords
subject
progression
cancer
pharmaceutical combination
pyridin
Prior art date
Application number
BR112022004465A
Other languages
English (en)
Inventor
Jiang Beibei
Yang Liu
Chen Cheng
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of BR112022004465A2 publication Critical patent/BR112022004465A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

MÉTODO PARA A PREVENÇÃO, RETARDO DE PROGRESSÃO OU TRATAMENTO DE CÂNCER EM UM SUJEITO E COMBINAÇÃO FARMACÊUTICA. É aqui fornecido um método para a prevenção, retardo de progressão ou tratamento de câncer em um sujeito, compreendendo administrar ao sujeito, em necessidade do mesmo, um inibidor de multi-tirosina quinase, N-(3-fluoro-4-((2-(5-(((2-metoxietil)amino)metil)piridin-2-il)tieno [3,2-b] piridin-7-il)oxi)fenil)-N-(4-fluorofenil)ciclopropano-1,1-dicarboxamida ou um sal farmaceuticamente aceitável da mesma, em combinação com um inibidor de checkpoint imunológico. Além disso, forneceu uma combinação farmacêutica compreendendo um inibidor de multi-tirosina quinase, N-(3-fluoro-4-((2-(5-(((2-metoxietil)amino)metil)piridin-2-il)tieno[3,2-b]piridin-7-il)oxi)fenil)-N-(4-fluoro fenil)ciclopropano-1,1-dicarboxamida ou um sal farmaceuticamente aceitável da mesma, em combinação com um inibidor de checkpoint imunológico e o uso do mesmo.
BR112022004465A 2019-09-11 2020-09-11 Método para a prevenção, retardo de progressão ou tratamento de câncer em um sujeito e combinação farmacêutica BR112022004465A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019105418 2019-09-11
PCT/CN2020/114703 WO2021047623A1 (en) 2019-09-11 2020-09-11 Treatment of cancer using a combination comprising multi-tyrosine kinase inhibitor and immune checkpoint inhibitor

Publications (1)

Publication Number Publication Date
BR112022004465A2 true BR112022004465A2 (pt) 2022-08-16

Family

ID=74866132

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022004465A BR112022004465A2 (pt) 2019-09-11 2020-09-11 Método para a prevenção, retardo de progressão ou tratamento de câncer em um sujeito e combinação farmacêutica

Country Status (13)

Country Link
US (1) US20220387404A1 (pt)
EP (1) EP4041304A4 (pt)
JP (1) JP2022548212A (pt)
KR (1) KR20220062030A (pt)
CN (1) CN114450025A (pt)
AU (1) AU2020344757A1 (pt)
BR (1) BR112022004465A2 (pt)
CA (1) CA3150514A1 (pt)
IL (1) IL291092A (pt)
MX (1) MX2022003095A (pt)
TW (1) TW202123936A (pt)
WO (1) WO2021047623A1 (pt)
ZA (1) ZA202202617B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3033827A1 (en) 2016-08-16 2018-02-22 Beigene, Ltd. Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl )-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide,preparation, and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3702373T3 (pl) * 2013-09-13 2022-12-05 Beigene Switzerland Gmbh Przeciwciała anty-PD1 i ich zastosowanie jako środki terapeutyczne i diagnostyczne
KR20240064733A (ko) * 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
WO2017205801A1 (en) * 2016-05-27 2017-11-30 Takeda Pharmaceutical Company Limited Combination of immunotherapy agents and spleen tyrosine kinase inhibitors
CN109963592B (zh) * 2017-06-05 2022-11-22 江苏恒瑞医药股份有限公司 Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途
JP2021502415A (ja) * 2017-11-10 2021-01-28 エレバー セラピューティクス，インク． 癌の処置のためのアパチニブを用いる併用療法

Also Published As

Publication number Publication date
WO2021047623A1 (en) 2021-03-18
US20220387404A1 (en) 2022-12-08
KR20220062030A (ko) 2022-05-13
CA3150514A1 (en) 2021-03-18
MX2022003095A (es) 2022-04-11
EP4041304A1 (en) 2022-08-17
CN114450025A (zh) 2022-05-06
EP4041304A4 (en) 2023-09-27
AU2020344757A1 (en) 2022-03-24
JP2022548212A (ja) 2022-11-17
ZA202202617B (en) 2022-11-30
TW202123936A (zh) 2021-07-01
IL291092A (en) 2022-05-01

Similar Documents

Publication Publication Date Title
BR112022009571A2 (pt) Uso de inibidor de fak na preparação de um fármaco para tratar tumores que têm mutação nras
MX2021002886A (es) Terapia de combinacion para el tratamiento de cancer de mama triple negativo.
CY1124432T1 (el) Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη
BR0110877A (pt) Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncer
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
BRPI0515896A (pt) composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus
EA200900638A1 (ru) СОЛИ И КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 2-МЕТИЛ-2-[4-(3-МЕТИЛ-2-ОКСО-8-ХИНОЛИН-3-ИЛ-2,3-ДИГИДРОИМИДАЗО[4,5-c]ХИНОЛИН-1-ИЛ)ФЕНИЛ]ПРОПИОНИТРИЛА
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
BRPI0414791A (pt) derivados de purina inibidores da replicação do hiv
FI3157527T3 (fi) Ezh2-inhibiittoreita lymfoman hoitoon
MX2021006575A (es) Composiciones y metodos para el tratamiento de trastornos del higado.
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
BR112018070017A2 (pt) métodos de tratamento de cânceres pediátricos
MX2021006552A (es) Antagonista del receptor del factor de liberacion de corticotropina 1 (crf1), formulaciones farmaceuticas y formas solidas del mismo para el tratamiento de hiperplasia suprarrenal congenita.
HUP0103078A2 (hu) Készítmények és eljárások szürkehályog kezelésére
WO2016133903A3 (en) Combination therapy for cancer treatment
NO20066080L (no) Behandling med irinotecan (CPT-11) og en AGFR-inhibitor
EA202090977A1 (ru) Новая комбинация активных агентов для лечения прогрессирующих фиброзирующих интерстициальных заболеваний легких (pf-ild)
MX2015017629A (es) Combinaciones farmaceuticas.
EP3915985A4 (en) PYRROLOPYRIDINE DERIVATIVE AND ITS USE IN THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISEASE
WO2018027084A3 (en) Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
BR112021022843A2 (pt) Composto para tratamento de gota ou hiperuricemia
EA201691555A1 (ru) Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени
BR112022004465A2 (pt) Método para a prevenção, retardo de progressão ou tratamento de câncer em um sujeito e combinação farmacêutica